[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nsaid-induced-peptic-ulcer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nsaid-induced-peptic-ulcer":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100635901","fexuclue-for-prevention-of-nsaids-induced-peptic-ulcer-in-real-world-practice-100635901",false,"NCT07558707","Fexuclue for Prevention of NSAIDs-Induced Peptic Ulcer in Real-World Practice","A Prospective, Multi-Center, Observational Study to Evaluate the Efficacy and Safety of Fexuclue Tablet 20 mg in Patients Requiring NSAIDs-Induced Peptic Ulcer Prevention","Inclusion Criteria:\n\n* Adults aged ≥19 years\n* Patients requiring NSAIDs therapy\n* Patients requiring prevention of NSAIDs-induced peptic ulcer\n* Patients prescribed Fexuclue Tablet 20 mg\n* Patients who provide written informed consent\n\nExclusion Criteria:\n\n* Hypersensitivity to Fexuclue or its components\n* Severe hepatic impairment\n* Pregnant or breastfeeding women\n* Patients considered inappropriate by investigator","ALL","19 Years",{"count":19,"type":20},7000,"ESTIMATED","OBSERVATIONAL","This study is a prospective, multi-center, observational study to evaluate the efficacy and safety of Fexuclue Tablet 20 mg in patients requiring prevention of NSAIDs-induced peptic ulcer in real-world clinical practice in Korea.\n\nPatients receiving NSAIDs and requiring gastroprotective therapy will be enrolled and followed prospectively. The study will assess patient-reported outcomes (PROs) related to gastrointestinal symptoms, as well as safety outcomes.",[24,25],"Peptic Ulcer","NSAID-Induced Peptic Ulcer",[27,28,29,30,31],"NSAIDs","Fexuprazan","PRO","Real-World","Peptic Ulcer Prevention","NOT_YET_RECRUITING","2026-04-27",{"date":35,"type":36},"2026-04-30","ACTUAL",{"date":35,"type":20},{"date":39,"type":20},"2027-12-31",{"name":41,"class":42},"Daewoong Pharmaceutical Co. LTD.","INDUSTRY"]